Results 131 to 140 of about 27,201 (202)

Repurposing of lansoprazole and nitazoxanide as NR2F2 inhibitors in the gastric cancer cell line GCIY: computational insights and siRNA-mediated <i>in vitro</i> tests. [PDF]

Front Chem
Culletta G, Roomi MS, Caricasulo MA, Zanetti A, Terao M, Paroni G, Garattini E, Tutone M.   +7 more
europepmc   +1 more source

Annexin A6 Modulates the Secretion of Pro-Inflammatory Cytokines and Exosomes via Interaction with SNAP23 in Triple-Negative Breast Cancer Cells. [PDF]

Cells
Sakwe NI, Korolkova OY, Vuong NB, Edwards AD, Black PJ, Ball DD, McIntosh AR, Thomas PL, Whalen Melvin DS, Beasley HK, Hinton AO, Ochieng J, Sakwe AM.   +12 more
europepmc   +1 more source

Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices. [PDF]

Breast Cancer (Dove Med Press)
Kullab S, Refae A, Altwairgi A, Abusanad A, Elsamany S, Abdelhafiez NA, Basulaiman B, Zahralliyali A, Alshangiti AA, Al-Mubarak M, Alwbari A, Alharbi A, Osman A, Kiwan H, Alaklabi S.   +14 more
europepmc   +1 more source

Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation. [PDF]

Clin Cancer Res
Bharadwaj S, Corredor G, Al-Shakhshir H, Medina S, Almahfouz SN, Dhamdhere R, Pathak T, Fu P, Liu Y, Gandhi S, Badve S, Madabhushi A.   +11 more
europepmc   +1 more source

A Phase 1 Dose Escalation of Lapatinib and Paclitaxel in Recurrent Ovarian Cancer. [PDF]

Cancers (Basel)
Cao CD, McCorkle JR, Yan D, Esfahani HS, Jayswal R, Piecoro D, Li N, Baldwin LA, Miller RW, Desimone CP, Dietrich CS, Ueland FR, Kolesar JM.   +12 more
europepmc   +1 more source

Design, synthesis, and biological evaluation of quinolin-2-one/thiazole hybrids as multi-targeted antiproliferative agents inducing caspase-dependent apoptosis. [PDF]

Sci Rep
Al-Wahaibi LH, Alzahrani AYA, Bräse S, Tawfeek HN, Youssif BGM.   +4 more
europepmc   +1 more source

MUC16 promotes endometrial cancer progression and modulates sensitivity to lapatinib through the ESR1/PI3K/AKT axis. [PDF]

Transl Oncol
Yu Y, Lv S, Li G, Sun L, Su S.
europepmc   +1 more source

Correction to "[NSUN2 promotes colorectal cancer progression and increases lapatinib sensitivity by enhancing CUL4B/ErbB-STAT3 signalling in a non-m5C manner]". [PDF]

Clin Transl Med
europepmc   +1 more source

A degrader of HER2 and EGFR abolishes p95HER2 and shows robust antitumor efficacy in HER2-positive breast cancer. [PDF]

Sci Rep
Yang L, Bhattacharya A, Li Y, Peterson D, Zhang Y.   +4 more
europepmc   +1 more source

Tumor-Intrinsic PD-1 Regulatory Network Drives Lapatinib Resistance in HER2⁺ Breast Cancer: An Integrative Bioinformatics Analysis. [PDF]

Asian Pac J Cancer Prev
Alhallaq AS, Sultan NS.
europepmc   +1 more source